老年CHC临床特点及抗病毒治疗策略研究进展

doi:10.3969/j.issn.1672-5069.2018.06.043

摘要/Abstract

摘要： 由于患者老龄化和病程不断延长,老年慢性丙型肝炎（chronic hepatitis C,CHC）患者的治疗越来越受到关注。由于老年患者感染丙型肝炎病毒（HCV）的时间较长,罹患肝硬化和肝癌的风险较高。老年丙型肝炎患者可能还伴有多种肝外基础疾病,如恶性肿瘤、肾脏疾病、糖尿病、心血管疾病和神经认知障碍等。目前,新型直接抗病毒药物（DAA）对老年CHC患者的抗病毒治疗效果和相关并发症情况尚不明了。有限的有关DAA治疗老年CHC患者的研究资料表明,年龄不应成为DAA治疗的障碍。

关键词: CHC, 直接抗病毒药物, 肝硬化, 肝癌, 老年

Abstract: Hepatitis C virus（HCV） infection is of concern in elderly patients because the proportion of patients with prolonged duration of infection increases gradually,which might be associated with an increased risk of HCV infection-associated liver diseases,includingcirrhosis and hepatocellular carcinoma. The patients with chronic hepatitis C（CHC） at this ages tends to be accompanied with underlying diseases,such as malignancy,kidney disease,diabetes,cardiovascular disease,and neurocognitive impairment. The efficacy of new direct-acting antiviral agents （DAA） for the treatment of elderly patients with CHC is still under investigation,and the safety needs further observations.

Key words: Hepatitis C, Direct-acting antiviral agents, Liver cirrhosis, Hepatocellular carcinoma, Elderly

嵇小琴综述, 龚健审校. 老年CHC临床特点及抗病毒治疗策略研究进展[J]. 实用肝脏病杂志, 2018, 21(6): 995-998.

Ji Xiaoqin, Gong Jian.. Clinical features and antiviral treatment of elderly patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 995-998.

参考文献

[1] Liu Z,Yang Q,Shi O,et al.The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014:An observational population-based study. J Viral Hepat,2018,20:1-12.
[2] Armstrong GL,Wasley A,Simard EP,et al.The prevalence of hepatitis C virus infection in the United States,1999 through 2002. Ann Intern Med,2006,144(10):705-714.
[3] Rein DB,Smith BD,Wittenborn JS,et al.The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med,2012,156(4):263-270.
[4] Denniston MM,Jiles RB,Drobeniuc J,et al.Chronic hepatitis C virus infection in the United States,National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med,2014,160(5):293-300.
[5] Davis GL,Albright JE,Cook SF,et al.Projecting future complications of chronic hepatitis C in the United States. Liver Transpl,2003,9(4):331-338.
[6] Tong MJ,el-Farra NS,Reikes AR,et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med,1995,332(22):1463-1466.
[7] Minola E,Prati D,Suter F,et al.Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood,2002,99(12):4588-4591.
[8] Chou JP,Effros RB.T cell replicative senescence in human aging. Curr Pharm Des,2013,19(9):1680-1698.
[9] Mangia A,Ripoli M.Insulin resistance,steatosis and hepatitis C virus. Hepatol Int,2013,7(Suppl 2):782-789.
[10] Younossi ZM,Stepanova M,Nader F,et al.Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther,2013,37(6):647-652.
[11] Mehta SH,Brancati FL,Strathdee SA,et al.Hepatitis C virus infection and incident type 2 diabetes. Hepatology,2003,38(1):50-56.
[12] Mehta SH,Strathdee SA,Thomas DL.Association between hepatitis C virus infection and diabetes mellitus. Epidemiol Rev,2001,23(2):302-312.
[13] Kawaguchi Y,Mizuta T.Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol,2014,20(11):2888-2901.
[14] Kawaguchi T,Ide T,Taniguchi E,et al.Clearance of HCV improves insulin resistance,beta-cell function,and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol,2007,102(3):570-576.
[15] Mahale P,Torres HA,Kramer JR,et al.Hepatitis C virus infection and the risk of cancer among elderly US adults:a registry-based case-control study. Cancer,2017,123(7):1202-1211.
[16] Zignego AL,Giannini C,Gragnani L.HCV and lymphoproliferation. Clin Dev Immunol,2012,2012:980942.
[17] Oliveira CP,Kappel CR,Siqueira ER,et al.Effects of hepatitis C virus on cardiovascular risk in infected patients:a comparative study. Int J Cardiol,2013,164(2):221-226.
[18] Boddi M,Abbate R,Chellini B,et al.Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol,2010,47(1):72-75.
[19] Hassoun Z,Willems B,Deslauriers J,et al.Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci,2002,47(12):2674-2781.
[20] Forton DM. Altered monoaminergic transporter binding in hepatitis C related cerebral dysfunction:a neuroimmunologial condition Gut,2006,55(11):1535-1537.
[21] Casato M,Saadoun D,Marchetti A,et al.Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis:a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. J Rheumatol,2005,32(3):484-488.
[22] Weissenborn K,Ennen JC,Bokemeyer M,et al.Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut,2006,55(11):1624-1630.
[23] Fontana RJ,Bieliauskas LA,Back-Madruga C,et al.Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol,2005,43(4):614-622.
[24] Laskus T,Radkowski M,Bednarska A,et al.Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol,2002,76(19):10064-10068.
[25] Paulino AD,Ubhi K,Rockenstein E,et al.Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. J Neurovirol,2011,17(4):327-340.
[26] Molnar MZ,Alhourani HM,Wall BM,et al.Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology,2015,61(5):1495-1502.
[27] Fischer MJ,Wyatt CM,Gordon K,et al.Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr,2010,53(2):222-226.
[28] Sato I,Shimbo T,Kawasaki Y,et al.Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan:a retrospective study using the Japanese Interferon Database. Hepatol Res,2015,45(8):829-836.
[29] El-Serag HB,Kramer J,Duan Z,et al.Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat,2016,23(9):687-696.
[30] Ioannou GN,Beste LA,Chang MF,et al. Effectiveness of sofosbuvir,ledipasvir/sofosbuvir,or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology,2016,151(3):457-471.e5.
[31] Saab S,Park SH,Mizokami M,et al.Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology,2016,63(4):1112-1119.
[32] Su F,Beste LA,Green PK,et al.Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients:a real-world study of 17 487 patients. Eur J Gastroenterol Hepatol,2017,29(6):686-693.
[33] El-Serag HB,Kanwal F,Richardson P,et al.Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology,2016,64(1):130-137.
[34] Thein HH,Maruff P,Krahn MD,et al.Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med,2007,8(8):520-528.